Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWA24P)

• Drug Name: IPI-145 Drug Info
• Synonyms: Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI

Indication

Disease Entry	ICD 11	Status	REF
Follicular lymphoma	2A80	Approved	[1]
Small lymphocytic lymphoma	2A82.0	Approved	[1]
Arthritis	FA20	Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 50905713
  ChEBI ID: CHEBI:131169
  CAS Number: CAS 1201438-56-3
  TTD Drug ID: DMWA24P
  VARIDT Drug ID: DR00276
  ACDINA Drug ID: D01025

Molecule-Related Drug Atlas

Drug(s) Targeting PI3-kinase delta (PIK3CD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[4]
Idelalisib	DM602WT	Chronic lymphocytic leukaemia	2A82.0	Approved	[5]
Umbralisib	DMYRBO1	Follicular lymphoma	2A80	Approved	[6]
Leniolisib	DMWAD93	Stomach cancer	2B72	Approved	[7]
Buparlisib	DM1WEHC	Breast cancer	2C60-2C65	Phase 3	[8]
INCB50465	DMZJP2T	Diffuse large B-cell lymphoma	2A81	Phase 2	[9]
ME-401	DMK0UOY	Follicular lymphoma	2A80	Phase 2	[9]
RP6530	DMYILGK	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[9]
Parsaclisib	DMYBIFS	Follicular lymphoma	2A80	Phase 2	[10]
AZD8154	DMK13L1	Asthma	CA23	Phase 2	[11]

Drug(s) Targeting PI3-kinase gamma (PIK3CG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[12]
Buparlisib	DM1WEHC	Breast cancer	2C60-2C65	Phase 3	[8]
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[9]
Rigosertib	DMOSTXF	Myelodysplastic syndrome	2A37	Phase 3	[13]
GDC-0032	DMT4QHD	Breast cancer	2C60-2C65	Phase 3	[9]
PQR309	DMMCYZ8	Squamous head and neck cell carcinom	2D60.0	Phase 2	[14]
SAR245409	DMQM7IL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]
XL147	DMML7BE	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]
SF1126	DML10K3	Head and neck cancer	2D42	Phase 2	[16]
PF-05212384	DMBL3VD	Solid tumour/cancer	2A00-2F9Z	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3-kinase delta (PIK3CD)	TTGBPJE	PK3CD_HUMAN	Modulator	[3]
PI3-kinase gamma (PIK3CG)	TTHBTOP	PK3CG_HUMAN	Modulator	[3]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7795).
• [3] PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
• [4] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [5] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [7] Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316.
• [8] Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.
• [11] Discovery of AZD8154, a Dual PI3Kgamma-delta Inhibitor for the Treatment of Asthma. J Med Chem. 2021 Jun 24;64(12):8053-8075.
• [12] BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30.
• [13] Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
• [16] An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81.
• [17] First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95.